- Home
- ANY vs ICU Comparison
ANY vs ICU Comparison
Compare ANY & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANY | ICU |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 13.8M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANY | ICU |
|---|---|---|
| Price | $2.42 | $3.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | ★ 512.7K | 70.1K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,181,000.00 | $1,234,000.00 |
| Revenue This Year | $15.62 | $53.00 |
| Revenue Next Year | N/A | $50.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 814.07 |
| 52 Week Low | $0.16 | $0.22 |
| 52 Week High | $6.20 | $5.38 |
Technical Indicators
Market Signals| Indicator | ANY | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 42.71 |
| Support Level | $1.24 | $2.21 |
| Resistance Level | $2.49 | $4.96 |
| Average True Range (ATR) | 0.23 | 0.24 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 52.69 | 28.09 |
Price Performance
Historical ComparisonAbout ANY Sphere 3D Corp.
Sphere 3D Corp is engaged in the Bitcoin mining business. The company has established an enterprise-scale mining operation through the procurement of mining equipment and partnering with experienced service providers. It generates revenue from mining and selling Bitcoin.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.